Bespoke Extracts (BSPK) 10-Q 20 Apr 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Feb. 28, 2021	Apr. 19, 2021
Document Information Line Items
Entity Registrant Name	Bespoke Extracts, Inc.
Document Type	10-Q
Current Fiscal Year End Date	--08-31
Entity Common Stock, Shares Outstanding		246,889,621
Amendment Flag	false
Entity Central Index Key	0001409197
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Feb. 28, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity File Number	000-52759
Entity Incorporation, State or Country Code	NV
Entity Interactive Data Current	Yes

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Feb. 28, 2021	Aug. 31, 2020
Current assets
Cash	$ 501,560	$ 126,603
Accounts receivable, net	3,814	3,585
Prepaid expense	55,826	2,319
Inventory, net	48,206
Total current assets	609,406	132,507
Furniture and equipment	2,745
Domain names, net of amortization of $12,494 and $10,872, respectively	34,369	33,741
Total assets	646,520	166,248
Current liabilities
Accounts payable and accrued liabilities	115,928	59,913
Note payable - related party	534	120,000
Convertible notes	500,000	500,000
Total current liabilities	616,462	679,913
Commitments and contingencies (Note 7)
Stockholders’ Equity (Deficit)
Preferred stock, value
Common stock, $0.001 par value: 3,000,000,000 authorized; 246,888,426 and 194,388,426 shares issued and outstanding as of February 28, 2021 and August 31, 2020, respectively	246,889	194,389
Additional paid-in capital	19,066,135	17,992,635
Common stock payable		76,000
Accumulated deficit	(19,282,966)	(18,776,689)
Total stockholders' equity (deficit)	30,058	(513,665)
Total liabilities and stockholders' equity (deficit)	646,520	166,248
Series A Convertible Preferred Stock
Stockholders’ Equity (Deficit)
Preferred stock, value
Total stockholders' equity (deficit)
Series C Convertible Preferred Stock
Stockholders’ Equity (Deficit)
Preferred stock, value
Total stockholders' equity (deficit)

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Feb. 28, 2021	Aug. 31, 2020
Net of amortization cost (in Dollars)	$ 12,494	$ 10,872
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	246,888,426	194,388,426
Common stock, shares outstanding	246,888,426	194,388,426
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Series A Convertible Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Preferred stock, designated shares	1,000	1,000
Series C Convertible Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1
Preferred stock, designated shares	1	1

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2021	Feb. 29, 2020	Feb. 28, 2021	Feb. 29, 2020
Income Statement [Abstract]
Sales	$ 4,028		$ 11,567	$ 1,739
Cost of products sold	1,969		4,016	1,087
Gross Profit	2,059		7,551	652
Operating expenses:
Selling, general and administrative expenses	202,711	$ 190,928	345,083	432,430
Professional fees	40,208	93,411	62,623	148,786
Consulting	62,500	32,000	104,500	133,500
Amortization expense of domain name	811	1,150	1,622	1,986
Total operating expenses	306,230	317,489	513,828	716,702
Loss from operations	(304,171)	(317,489)	(506,277)	(716,050)
Other expense
Loss on settlement of debt		(89,595)		(89,595)
Interest expense and amortization of debt discount		(275,656)		(293,500)
Total other expense		(365,251)		(383,095)
Loss before income tax	(304,171)	(682,740)	(506,277)	(1,099,145)
Provision for income tax
Net Loss	$ (304,171)	$ (682,740)	$ (506,277)	$ (1,099,145)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic and Diluted (in Shares)	234,677,315	109,055,093	217,184,006	97,749,658
LOSS PER COMMON SHARE OUTSTANDING
Basic and Diluted (in Dollars per share)	$ 0	$ (0.01)	$ 0	$ (0.01)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Feb. 28, 2021	Feb. 29, 2020
Cash flows from operating activities
Net Loss	$ (506,277)	$ (1,099,145)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization expense of domain names	1,622	1,986
Amortization of debt discounts		293,500
Bad debt expense		2,981
Loss on settlement of debt		89,595
Option and warrant expense		316,585
Common stock issued for services		40,500
Accounts receivable	(229)	(165)
Inventory	(48,206)	(363)
Prepaid expense	(53,507)	1,907
Accounts payable and accrued liabilities	56,015	9,933
Net cash used in operating activities	(550,582)	(342,686)
Cash flows from investing activities
Purchase of Url	(2,250)
Purchase of equipment	(2,745)
Net cash used in investing activities	(4,995)
Cash flow from financing activities
Proceeds from convertible debt		400,000
Proceeds from note payable - related party	130,534
Repayment of debt		(120,000)
Repurchase of common stock		(27,500)
Sale of common stock	800,000	125,000
Net cash provided by financing activities	930,534	377,500
Net increase in cash and cash equivalents	374,957	34,814
Cash and cash equivalents at beginning of period	126,603	10,343
Cash and cash equivalents at end of period	501,560	45,157
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes
Noncash investing and financing activities:
Discount due beneficial conversion feature		281,300
Stock issued with convertible debt		118,700
Stock issued for conversion of debt - related party	250,000
Stock issued for stock payable	76,000
Preferred stock issued for the conversion of accrued salary		24,000
Assignment of URL for settlement of debt		$ 5,282

Condensed Statement of Stockhol

Condensed Statement of Stockholders’ Equity (Deficit) - USD ($)	Series A Preferred Shares Outstanding	Series B Preferred Shares Outstanding	Series C Preferred Shares Outstanding	Common Shares Outstanding	Additional Paid in Capital	Common Stock Payable	Accumulated Deficit	Total
Balance at Aug. 31, 2019				$ 78,156	$ 13,950,095	$ 76,000	$ (14,135,883)	$ (31,632)
Balance (in Shares) at Aug. 31, 2019				78,155,093
Preferred stock issued for the conversion of accrued salary		$ 1			23,999			24,000
Preferred stock issued for the conversion of accrued salary (in Shares)		1
Sale of common stock				$ 20,833	104,167			125,000
Sale of common stock (in Shares)				20,833,333
Common stock issued for services				$ 4,500	36,000			40,500
Common stock issued for services (in Shares)				4,500,000
Warrant expense					316,585			316,585
Common stock issued with debt				$ 9,900	108,800			118,700
Common stock issued with debt (in Shares)				9,900,000
Repurchase of common stock				$ (3,000)	(24,500)			(27,500)
Repurchase of common stock (in Shares)				(3,000,000)
Beneficial conversion feature					281,300			281,300
Net loss							(1,099,145)	(1,099,145)
Balance at Feb. 29, 2020		$ 1		$ 110,389	14,796,446	76,000	(15,235,028)	(252,192)
Balance (in Shares) at Feb. 29, 2020		1		110,388,426
Balance at Nov. 30, 2019		$ 1		$ 105,389	14,341,227	76,000	(14,552,288)	(29,671)
Balance (in Shares) at Nov. 30, 2019		1		105,388,426
Options and warrant expense					160,219			160,219
Common stock issued with debt				$ 5,000	50,000			55,000
Common stock issued with debt (in Shares)				5,000,000
Beneficial conversion feature					245,000			245,000
Net loss							(682,740)	(682,740)
Balance at Feb. 29, 2020		$ 1		$ 110,389	14,796,446	76,000	(15,235,028)	(252,192)
Balance (in Shares) at Feb. 29, 2020		1		110,388,426
Balance at Aug. 31, 2020				$ 194,389	17,992,635	76,000	(18,776,689)	(513,665)
Balance (in Shares) at Aug. 31, 2020			1	194,388,426
Common stock for conversion of note payable - related party				$ 20,000	230,000			250,000
Common stock for conversion of note payable - related party (in Shares)				20,000,000
Exchange of common stock payable				$ 500	75,500	(76,000)
Exchange of common stock payable (in Shares)				500,000
Sale of common stock				$ 32,000	768,000			800,000
Sale of common stock (in Shares)				32,000,000
Net loss							(506,277)	(506,277)
Balance at Feb. 28, 2021				$ 246,889	19,066,135		(19,282,966)	30,058
Balance (in Shares) at Feb. 28, 2021			1	246,888,426
Balance at Nov. 30, 2020				$ 229,389	18,307,635	76,000	(18,978,795)	(365,771)
Balance (in Shares) at Nov. 30, 2020			1	229,388,426
Common stock issued for note payable				$ 5,000	95,000			100,000
Common stock issued for note payable (in Shares)				5,000,000
Exchange of common stock payable				$ 500	75,500	(76,000)
Exchange of common stock payable (in Shares)				500,000
Sale of common stock				$ 12,000	588,000			600,000
Sale of common stock (in Shares)				12,000,000
Net loss							(304,171)	(304,171)
Balance at Feb. 28, 2021				$ 246,889	$ 19,066,135		$ (19,282,966)	$ 30,058
Balance (in Shares) at Feb. 28, 2021			1	246,888,426

Nature of Operations, Significa

Nature of Operations, Significant Accounting Policies and Going Concern	6 Months Ended
	Feb. 28, 2021
Accounting Policies [Abstract]
NATURE OF OPERATIONS, SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN	1. NATURE OF OPERATIONS, SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN Nature of Business Operations Bespoke Extracts, Inc. (the “Company”) is a Nevada corporation focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products. The Company introduced its original line of CBD products in 2018. In the fall of 2020, the Company unveiled a new brand image, new website and ecommerce store and a new line-up of seven hemp-derived CBD formulations available for purchase in the form of tinctures and softgels. Basis of Presentation The accompanying condensed unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments consisting of a normal and recurring nature considered necessary for a fair presentation have been included. Operating results for the six months ended February 28, 2021 may not necessarily be indicative of the results that may be expected for the year ended August 31, 2021. For further information, refer to the Company’s financial statements and footnotes thereto included in the Annual Report on Form 10-K for the year ended August 31, 2020. Certain prior period amounts have been reclassified to conform to the current period presentation. Going Concern The accompanying condensed financial statements have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations, a working capital deficit and an accumulated deficit as of and for the six months ended February 28, 2021. This raises substantial doubt about our ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repaying its liabilities arising from normal business operations when they come due. There is no assurance that this series of events will be satisfactorily completed. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail or cease our operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence. These financial statements do not include any adjustments that might arise from this uncertainty. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements and accompanying notes. Significant estimates include the assumption used in the valuation of equity-based transactions, valuation of intangible assets, allowance for doubtful accounts and inventory valuation and reserves. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents include all highly liquid investments with original maturities of three months or less at the time of purchase. At February 28, 2021 and August 31, 2020, the Company did not have any cash equivalents. Fair Value of Financial Instruments The carrying amounts of cash, accounts receivable, prepaid expenses, inventory and other assets, accounts payable, accrued liabilities, note payable and convertible note payable approximate their fair values as of February 28, 2021 and August 31, 2020, respectively, because of their short-term natures and the Company’s borrowing rate of interest. Accounts Receivable Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. At February 28, 2021 and August 31, 2020, the Company has recorded an allowance for doubtful accounts of $2,981 and $2,981, respectively. At February 28, 2021 and August 31, 2020 included in the accounts receivable is the merchant holdback receivable balance of $3,636 and $3,585, respectively which will be remitted to the Company in the future. Inventory Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of February 28, 2021 and August 31, 2020, inventory amounted to $48,206 and $0, respectively, which consisted of finished goods of $39,296, and raw materials of $8,910 net of reserves. During the six months ended February 28, 2021 the Company adjusted the reserves by $6,776 for products sold. As of February 28, 2021 and August 31, 2020 inventory reserves were $33,476 and $40,252, respectively. Revenue Recognition We account for revenue in accordance with the Financial Accounting Standards Board (“FASB”) Our products are sold through our online and telephonic channels. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due on the date of shipment. The Company offers a 30 day return policy on sales. Stock Option Plans Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based on the fair value of the services provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable, and in accordance FASB ASC 718 , Compensation-Stock Compensation, Net Loss per Share Basic loss per share amounts are computed based on net loss divided by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock. The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted” method. The effect of 3,000,000 warrants and 0 options as well as 500,000,000 shares issuable upon the conversion of a convertible note are anti-dilutive for the three and six months ended February 28, 2021. The effect of 3,450,000 warrants and 1,200,000 options is anti-dilutive for the three and six months ended February 29, 2020.

Asset Purchase Agreement

Asset Purchase Agreement	6 Months Ended
	Feb. 28, 2021
Asset Purchase Agreement [Abstract]
ASSET PURCHASE AGREEMENT	2. ASSET PURCHASE AGREEMENT On February 21, 2017, the Company purchased all right, title, interest and goodwill in or associated with certain domain names set forth in an asset purchase agreement for a total of $20,185 in cash and 200,000 shares of the Company’s common stock valued at $30,000. During the year ended August 31, 2020, the Company transferred certain URLs valued at $5,282 to an unrelated party and impaired $289 leaving a balance of $44,614 of URL’s. The domain names are being amortized over a 15 year period. During the three and six months ended February 28, 2021, the Company recorded an amortization expense of $811 and $1,622, respectively. During the three and six months ended February 29, 2020, the Company recorded an amortization expense of $1,150 and $1,986, respectively.

Note Payable - Related Party

Note Payable - Related Party	6 Months Ended
	Feb. 28, 2021
Debt Disclosure [Abstract]
NOTE PAYABLE - RELATED PARTY	3. NOTE PAYABLE - RELATED PARTY On August 31, 2020, the Company issued a promissory note in the principal amount of $150,000, to Danil Pollack, the Company’s chief executive officer. Upon execution of the note, $120,000 was remitted and the remaining $30,000 was remitted on September 22, 2020. The note did not bear interest. On November 10, 2020, the Company entered into an exchange agreement with Mr. Pollack. Pursuant to the exchange agreement, Mr. Pollack exchanged the note issued August 31, 2020 with an outstanding principal amount of $150,000 for 15,000,000 shares of common stock of the Company. During the six months ended February 28, 2021, Mr. Pollack loaned the Company an additional $100,534 that was non-interest bearing and payable upon demand. $100,000 of this amount was subsequently deemed to be consideration for 5,000,000 shares of common stock the Company issued to Mr. Pollack on January 6, 2021.

Convertible Note Payable

Convertible Note Payable	6 Months Ended
	Feb. 28, 2021
Convertible Debenture Related Party [Abstract]
CONVERTIBLE NOTE PAYABLE	4. CONVERTIBLE NOTE PAYABLE On December 24, 2019, the Company entered into and closed a securities purchase agreement with an accredited investor, pursuant to which the Company issued and sold to the investor an original issue discount convertible debenture in the principal amount of $500,000, for a purchase price of $300,000. The Company also issued to the investor 5,000,000 shares of common stock valued at $55,000 ($.005 per share). The Company recorded beneficial conversion of $245,000 due to the conversion feature. The debenture may not be converted to common stock to the extent such conversion would result in the holder beneficially owning more than 4.99% of the Company’s outstanding common stock. The debenture had an original maturity date of April 30, 2020 and was convertible into shares of common stock of the Company at a conversion price of $0.001, except that, if the Company failed to repay the debenture upon maturity, the conversion price would be reduced to $0.0004 (subject to adjustment for stock splits, stock dividends, and similar transactions) and the debenture would bear interest at the rate of 9% per year. The Company’s obligation to repay the debenture upon maturity was initially secured by a security interest in the Company’s inventory pursuant to a security agreement between the Company and the investor. For the year ended August 31, 2020 the Company recorded amortization of debt discount of $500,000. On April 23, 2020, the Company entered into an amendment to the security agreement, dated December 24, 2019 between the Company and the holder of the Company’s original issue discount convertible debenture, dated December 24, 2019. Pursuant to the security agreement amendment, the collateral under the security agreement was amended to be the Company’s URLs. On December 10, 2020 the Company entered into amendments (“Amendment No. 3”) with the holders of the Company’s original issue discount convertible debentures, with an original issuance date of December 24, 2019, as amended by amendment No. 1 thereto, dated May 28, 2020, and amendment No. 2 thereto, dated August 21, 2020, in the aggregate outstanding principal amount of $500,000. Pursuant to Amendment No. 3, the maturity date of the debentures was extended to February 28, 2021. On January 15, 2021, the Company entered into amendments with the holders of the debentures, pursuant to which the conversion price of the debentures was increased to $0.05 per share (subject to adjustment for stock splits, stock dividends, and similar transactions). On April 20, 2021, the maturity date of the debentures was extended to May 31, 2021.

Equity

Equity	6 Months Ended
	Feb. 28, 2021
Stockholders' Equity Note [Abstract]
EQUITY	5. EQUITY Common Stock and Preferred Stock As of August 31, 2020, the Company had authorized capital of 800,000,000 shares of common stock with a par value of $0.001, and 50,000,000 shares of preferred stock with a par value of $0.001. On October 2, 2020, the Company filed a certificate of amendment to the Company’s articles of incorporation with the Secretary of State of Nevada, pursuant to which the Company increased its authorized shares of common stock from 800,000,000 to 3,000,000,000. 1,000 shares of preferred stock are designated as Series A Convertible Preferred Stock. No shares of Series A Preferred Stock are issued and outstanding as of August 31, 2020 and February 28, 2021 respectively. The Company’s Certificate of Designation of Series B Preferred Stock was withdrawn by the Company on June 30, 2020. 1 share of preferred stock is designated Series C Preferred Stock and is issued and outstanding as of August 31, 2020 and February 28, 2021, respectively. The Series C Preferred Stock has a stated value of $24,000 and entitles the holder to 51% of the total voting power of the Company’s stockholders. The Company may, in its sole discretion, redeem the Series C Preferred Stock at any time for a redemption price equal to the stated value. Upon payment of the redemption price by the Company, the Series C Preferred Stock will revert to the status of authorized but unissued preferred stock. Pursuant to a securities purchase agreement entered into on June 6, 2018 the Company was obligated to issue additional shares of common stock if the Company sold common stock at a price lower than $0.10 per share (or common stock equivalents with an exercise price less than $0.10 per share) during the six month period following the closing of the purchase agreement, in which event the Company was required to issue additional shares to the purchaser for no additional consideration, such that the total number of common stock received by the purchaser will be equal to $50,000 divided by lower financing price. As of August 31, 2020, the Company was obligated to issue 500,000 shares of common stock valued at $76,000. On January 5, 2021, the Company issued the 500,000 shares of common stock. On August 31, 2020, the Company issued a promissory note in the principal amount of $150,000, to Danil Pollack, the Company’s chief executive officer. Upon execution of the note, $120,000 was remitted and the remaining $30,000 was remitted on September 22, 2020. The note did not bear interest. On November 10, 2020, the Company entered into an exchange agreement with Mr. Pollack. Pursuant to the exchange agreement, Mr. Pollack exchanged the promissory note issued August 31, 2020 for 15,000,000 shares of common stock of the Company. During the six months ended February 28, 2021, Mr. Pollack loaned the Company an additional $100,534 that was non-interest bearing and payable upon demand. $100,000 of this amount was subsequently deemed to be consideration for 5,000,000 shares of common stock the Company issued to Mr. Pollack on January 6, 2021. On November 30, 2020, the Company entered into a securities purchase agreement with Danil Pollack. Pursuant to the purchase agreement, the Company issued and sold to Mr. Pollack 20,000,000 shares of common stock for an aggregate purchase price of $200,000. On January 21, 2021, the Company entered into a securities purchase agreement with Danil Pollack. Pursuant to the purchase agreement, the Company issued and sold to Mr. Pollack 2,000,000 shares of common stock for an aggregate purchase price of $100,000. On February 24, 2021, the Company entered into a securities purchase agreement with an accredited investor. Pursuant to the purchase agreement, the Company issued and sold to the investor 10,000,000 shares of common stock for an aggregate purchase price of $500,000. Warrants The following table summarizes the warrant activities during the six months ended February 28, 2021: Number of Weighted- Weighted- Outstanding at August 31, 2020 3,450,000 $ 0.56 2.8 years Granted - - Canceled or expired (450,000 ) 0.81 Exercised - - Outstanding at February 28, 2021 3,000,000 $ 0.52 2.53 years Exercisable at February 28, 2021 3,000,000 $ 0.52 2.53 years Intrinsic value at February 28, 2021 $ - Options On April 21, 2020, Danil Pollack was appointed president, chief executive officer, and chief financial officer of the Company. In connection with Mr. Pollack’s appointment, the Company entered into an employment agreement with Mr. Pollack. Pursuant to the employment agreement, Mr. Pollack will serve as the Company’s chief executive officer and president for a period of one year, which term will renew automatically for successive one year terms, subject to the right of either party to terminate the agreement at any time upon written notice. Mr. Pollack was granted the right, for a period of six months, to purchase up to 100,000,000 shares of common stock of the Company for a purchase price of $0.001 per share. The Company recognized option expense of $1,416,975 during the year ended August 31, 2020. During the year ended August 31, 2020, Mr. Pollack exercised 84,000,000 stock options for $84,000. During the six months ended February 28, 2021, the remaining 16,000,000 stock options expired. The following table summarizes the option activities during the six months ended February 28, 2021: Number of Weighted- Weighted- Outstanding at August 31, 2020 16,000,000 $ .001 0.9 years Granted - - Canceled or expired (16,000,000 ) .001 Exercised - - Outstanding at February 28, 2021 - $ - Exercisable at February 28, 2021 - $ -

Related Party Transactions

Related Party Transactions	6 Months Ended
	Feb. 28, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	6. RELATED PARTY TRANSACTIONS On September 30, 2020, the Company entered into an amendment to the Company’s employment agreement, dated April 22, 2020, with Danil Pollack, the Company’s chief executive officer. Pursuant to the amendment, the Company will pay Mr. Pollack an annual salary of $48,000. The Company may also in its discretion pay additional compensation to Mr. Pollack at any time as a bonus. See Note 7. On August 31, 2020, the Company issued a promissory note in the principal amount of $150,000, to Danil Pollack. Upon execution of the note, $120,000 was remitted and the remaining $30,000 was paid on September 22, 2020. The note did not bear interest. On November 10, 2020, the Company entered into an exchange agreement with Mr. Pollack. Pursuant to the exchange agreement, Mr. Pollack exchanged this note for 15,000,000 shares of common stock of the Company. See Note 5. During the six months ended November 30, 2020, Mr. Pollack loaned the Company an additional $100,534 that was non-interest bearing and payable upon demand. $100,000 of this amount was subsequently deemed to be consideration for 5,000,000 shares of common stock the Company issued to Mr. Pollack on January 6, 2021. See Note 5. On November 30, 2020, the Company entered into a securities purchase agreement with Mr. Pollack. Pursuant to the purchase agreement, the Company issued and sold to Mr. Pollack 20,000,000 shares of common stock for an aggregate purchase price of $200,000. See Note 5. On January 21, 2021, the Company entered into a securities purchase agreement with Danil Pollack. Pursuant to the purchase agreement, the Company issued and sold to Mr. Pollack 2,000,000 shares of common stock for an aggregate purchase price of $100,000. See Note 5.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Feb. 28, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	7. COMMITMENTS AND CONTINGENCIES Pursuant to a securities purchase agreement entered into on June 6, 2018 the Company was obligated to issue additional shares of common stock if the Company sold common stock at a price lower than $0.10 per share (or common stock equivalents with an exercise price less than $0.10 per share) during the six month period following the closing of the purchase agreement, in which event the Company was required to issue additional shares to the purchaser for no additional consideration, such that the total number of common stock received by the purchaser will be equal to $50,000 divided by lower financing price. As of November 30, 2020 and August 31, 2020, the Company was obligated to issue 500,000 shares of common stock valued at $76,000 which is included in the common stock payable in the accompanying balance sheet. On January 5, 2021, the Company issued 500,000 shares of common stock. On April 21, 2020, Danil Pollack was appointed president, chief executive officer, and chief financial officer of the Company. In connection with Mr. Pollack’s appointment, the Company entered into an employment agreement with Mr. Pollack. On September 30, 2020, the Company entered into an amendment to the employment agreement. Pursuant to the amendment, the Company will pay Mr. Pollack an annual salary of $48,000. The Company may also in its discretion pay additional compensation to Mr. Pollack at any time as a bonus. On October 13, 2020, the Company entered into a consulting agreement with Yaniv Rozen pursuant to which the Company engaged Mr. Rozen to serve as the Company’s chief operating officer on a consultant/independent contractor basis. Mr. Rozen may engage in other business activities while serving as the Company’s chief operating officer. Pursuant to the consulting agreement, the Company will pay Mr. Rozen a fee of $3,000 per month. The Company also agreed to issue to Mr. Rozen shares of common stock, and increase such monthly fee, as follows: ● Within five business day of the end of the fourth quarter of 2020, (i) if the Company’s average sales were at least $50,000 per month, for such quarter, the Company would issue to Mr. Rozen 500,000 shares of common stock; or (ii) if the Company’s average sales were at least $100,000 per month for such quarter, the Company would issue to Mr. Rozen 750,000 shares of common stock; ● Within five business day of the end of the first quarter of 2021, (i) if the Company’s average sales were at least $100,000 per month for such quarter, the Company will issue to Mr. Rozen 750,000 shares of common stock, or (ii) if the Company’s average sales were at least $150,000 per month for such quarter, the Company will issue to Mr. Rozen 1,000,000 shares of common stock, and will increase Mr. Rozen’s fee to $5,000 per month effective commencing at the end such quarter; ● Within five business days of the end of the second quarter of 2021, (i) if the Company’s average sales were at least $200,000 per month, for such quarter, the Company will issue to Mr. Rozen 1,500,000 shares of common stock, or (ii) if the Company’s average sales were at least $300,000 per month, for such quarter, the Company will issue to Mr. Rozen 2,000,000 shares of common stock; and ● Within five business days of the end of the third quarter of 2021, (i) if the Company’s average sales were at least $300,000 per month, for such quarter, the Company will issue to Mr. Rozen 2,000,000 shares of common stock; or (ii) if the Company’s average sales were at least $500,000 per month, for such quarter, the Company will issue to Mr. Rozen 3,000,000 shares of common stock, and will increase Mr. Rozen’s fee to $7,000 per month effective commencing at the end such quarter. As of February 28, 2021, there was no common stock owed to Mr. Rozen as the quarterly target sales were not met. The COVID-19 pandemic may negatively affect our operations, including by limiting access to our facilities, customers, management, and professional advisors, and causing delays and constraints in manufacturing and shipping of our products. These factors, in turn, may negatively impact our operations, financial condition and demand for our products, and our ability to raise capital on acceptable terms, or at all.

Major Customers

Major Customers	6 Months Ended
	Feb. 28, 2021
Risks and Uncertainties [Abstract]
MAJOR CUSTOMERS	8. MAJOR CUSTOMERS At February 28, 2021 and August 31, 2020, no individual customer amounted to over 10% of total accounts receivable. During the three and six months ended February 28, 2021 and February 29, 2020 no individual customer amounted to over 10% of total sales.

Subsequent Events

Subsequent Events	6 Months Ended
	Feb. 28, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENTS On April 20, 2021, the maturity date of the convertible debentures with an original issuance date of December 24, 2019 (see Note 4) was extended to May 31, 2021.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Feb. 28, 2021
Accounting Policies [Abstract]
Nature of Business Operations	Nature of Business Operations Bespoke Extracts, Inc. (the “Company”) is a Nevada corporation focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products. The Company introduced its original line of CBD products in 2018. In the fall of 2020, the Company unveiled a new brand image, new website and ecommerce store and a new line-up of seven hemp-derived CBD formulations available for purchase in the form of tinctures and softgels.
Basis of Presentation	Basis of Presentation The accompanying condensed unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments consisting of a normal and recurring nature considered necessary for a fair presentation have been included. Operating results for the six months ended February 28, 2021 may not necessarily be indicative of the results that may be expected for the year ended August 31, 2021. For further information, refer to the Company’s financial statements and footnotes thereto included in the Annual Report on Form 10-K for the year ended August 31, 2020. Certain prior period amounts have been reclassified to conform to the current period presentation.
Going Concern	Going Concern The accompanying condensed financial statements have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations, a working capital deficit and an accumulated deficit as of and for the six months ended February 28, 2021. This raises substantial doubt about our ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repaying its liabilities arising from normal business operations when they come due. There is no assurance that this series of events will be satisfactorily completed. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail or cease our operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence. These financial statements do not include any adjustments that might arise from this uncertainty.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements and accompanying notes. Significant estimates include the assumption used in the valuation of equity-based transactions, valuation of intangible assets, allowance for doubtful accounts and inventory valuation and reserves. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include all highly liquid investments with original maturities of three months or less at the time of purchase. At February 28, 2021 and August 31, 2020, the Company did not have any cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of cash, accounts receivable, prepaid expenses, inventory and other assets, accounts payable, accrued liabilities, note payable and convertible note payable approximate their fair values as of February 28, 2021 and August 31, 2020, respectively, because of their short-term natures and the Company’s borrowing rate of interest.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. At February 28, 2021 and August 31, 2020, the Company has recorded an allowance for doubtful accounts of $2,981 and $2,981, respectively. At February 28, 2021 and August 31, 2020 included in the accounts receivable is the merchant holdback receivable balance of $3,636 and $3,585, respectively which will be remitted to the Company in the future.
Inventory	Inventory Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of February 28, 2021 and August 31, 2020, inventory amounted to $48,206 and $0, respectively, which consisted of finished goods of $39,296, and raw materials of $8,910 net of reserves. During the six months ended February 28, 2021 the Company adjusted the reserves by $6,776 for products sold. As of February 28, 2021 and August 31, 2020 inventory reserves were $33,476 and $40,252, respectively.
Revenue Recognition	Revenue Recognition We account for revenue in accordance with the Financial Accounting Standards Board (“FASB”) Our products are sold through our online and telephonic channels. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due on the date of shipment. The Company offers a 30 day return policy on sales.
Stock Option Plans	Stock Option Plans Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based on the fair value of the services provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable, and in accordance FASB ASC 718 , Compensation-Stock Compensation,
Net Loss per Share	Net Loss per Share Basic loss per share amounts are computed based on net loss divided by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock. The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted” method. The effect of 3,000,000 warrants and 0 options as well as 500,000,000 shares issuable upon the conversion of a convertible note are anti-dilutive for the three and six months ended February 28, 2021. The effect of 3,450,000 warrants and 1,200,000 options is anti-dilutive for the three and six months ended February 29, 2020.

Equity (Tables)

Equity (Tables)	6 Months Ended
	Feb. 28, 2021
Stockholders' Equity Note [Abstract]
Schedule of warrants	Number of Weighted- Weighted- Outstanding at August 31, 2020 3,450,000 $ 0.56 2.8 years Granted - - Canceled or expired (450,000 ) 0.81 Exercised - - Outstanding at February 28, 2021 3,000,000 $ 0.52 2.53 years Exercisable at February 28, 2021 3,000,000 $ 0.52 2.53 years Intrinsic value at February 28, 2021 $ -
Schedule of stock options	Number of Weighted- Weighted- Outstanding at August 31, 2020 16,000,000 $ .001 0.9 years Granted - - Canceled or expired (16,000,000 ) .001 Exercised - - Outstanding at February 28, 2021 - $ - Exercisable at February 28, 2021 - $ -

Nature of Operations, Signifi_2

Nature of Operations, Significant Accounting Policies and Going Concern (Details) - USD ($)	6 Months Ended		12 Months Ended
	Feb. 28, 2021	Feb. 29, 2020	Aug. 31, 2020
Nature of Operations, Significant Accounting Policies and Going Concern (Details) [Line Items]
Allowance for doubtful accounts	$ 2,981		$ 2,981
Inventory	3,636		3,585
Inventory, net	48,206
Inventory finished goods	39,296
Raw material, net reserve			8,910
Adjusted reserves	6,776
Inventory	$ 33,476		$ 40,252
Shares issuable conversion of a convertible note (in Shares)	500,000,000
Options [Member]
Nature of Operations, Significant Accounting Policies and Going Concern (Details) [Line Items]
Anti-dilutive shares of warrants and options (in Shares)	0	1,200,000
Warrant [Member]
Nature of Operations, Significant Accounting Policies and Going Concern (Details) [Line Items]
Anti-dilutive shares of warrants and options (in Shares)	3,000,000	3,450,000

Asset Purchase Agreement (Detai

Asset Purchase Agreement (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2021	Feb. 29, 2020	Feb. 28, 2021	Feb. 29, 2020	Aug. 31, 2020	Feb. 21, 2017
Asset Purchase Agreement [Abstract]
Total approximate amount include in asset purchase agreement						$ 20,185
Number of common stock (in Shares)						200,000
Common stock value						$ 30,000
Transferred certain URLs values to holder					$ 5,282
Impairment expense					289
Repaid of note holder					$ 44,614
Amortized over period					15 years
Amortization expense	$ 811	$ 1,150	$ 1,622	$ 1,986

Note Payable - Related Party (D

Note Payable - Related Party (Details) - USD ($)	Jan. 06, 2021	Aug. 31, 2020	Feb. 28, 2021	Jan. 05, 2021	Nov. 30, 2020
Debt Disclosure [Abstract]
Principal amount		$ 150,000
Related party, description		Upon execution of the note, $120,000 was remitted and the remaining $30,000 was remitted on September 22, 2020. The note did not bear interest. On November 10, 2020, the Company entered into an exchange agreement with Mr. Pollack. Pursuant to the exchange agreement, Mr. Pollack exchanged the note issued August 31, 2020 with an outstanding principal amount of $150,000 for 15,000,000 shares of common stock of the Company.
Non-interest bearing payable			$ 100,534
Issued amount	$ 100,000
Issued shares (in Shares)	5,000,000			500,000	500,000

Convertible Note Payable (Detai

Convertible Note Payable (Details) - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Dec. 24, 2019	Feb. 28, 2021	Aug. 31, 2020	Jan. 15, 2021
Convertible Note Payable (Details) [Line Items]
Principal amount	$ 500,000		$ 500,000
Purchase amount	$ 300,000
Conversion per value (in Dollars per share)	$ 0.005			$ 0.05
Beneficial conversion feature	$ 245,000
Conversion rate, description	more than 4.99%
Maturity date	Apr. 30, 2020	Feb. 28, 2021
Conversion price (in Dollars per share)	$ 0.001
Conversion price reduced per share (in Dollars per share)	$ 0.0004
Bear interest rate	9.00%
Securities Purchase Agreement [Member]
Convertible Note Payable (Details) [Line Items]
Amortization of debt discount			$ 500,000
Investor [Member]
Convertible Note Payable (Details) [Line Items]
Issuance of common shares (in Shares)	5,000,000
Common stock value	$ 55,000

Equity (Details)

Equity (Details) - USD ($)	Jan. 06, 2021	Oct. 02, 2020	Apr. 21, 2020	Jun. 06, 2018	Feb. 24, 2021	Jan. 21, 2021	Nov. 30, 2020	Aug. 31, 2020	Feb. 28, 2021	Jan. 05, 2021
Equity (Details) [Line Items]
Common stock, shares authorized								800,000,000
Common stock, par value								$ 0.001	$ 0.001
Preferred stock, shares authorized								50,000,000	50,000,000
Preferred stock, par value								$ 0.001	$ 0.001
Description of stock		On October 2, 2020, the Company filed a certificate of amendment to the Company’s articles of incorporation with the Secretary of State of Nevada, pursuant to which the Company increased its authorized shares of common stock from 800,000,000 to 3,000,000,000. 1,000 shares of preferred stock are designated as Series A Convertible Preferred Stock.
Debt instrument, annual principal amount								$ 150,000
Additional amount									$ 100,534
Amount deemed consideration	$ 100,000
Common stock share issued	5,000,000						500,000			500,000
Common stock aggregate shares					10,000,000	2,000,000	20,000,000
Common stock aggregate amount					$ 500,000	$ 100,000	$ 200,000
Securities Purchase Agreement [Member]
Equity (Details) [Line Items]
Common stock share issued								500,000
Investor [Member] | Securities Purchase Agreement [Member]
Equity (Details) [Line Items]
Description of common stock				on June 6, 2018 the Company was obligated to issue additional shares of common stock if the Company sold common stock at a price lower than $0.10 per share (or common stock equivalents with an exercise price less than $0.10 per share) during the six month period following the closing of the purchase agreement, in which event the Company was required to issue additional shares to the purchaser for no additional consideration, such that the total number of common stock received by the purchaser will be equal to $50,000 divided by lower financing price. As of August 31, 2020, the Company was obligated to issue 500,000 shares of common stock valued at $76,000. On January 5, 2021, the Company issued the 500,000 shares of common stock.
Series C Preferred Stock [Member]
Equity (Details) [Line Items]
Preferred stock, par value								$ 0.001	$ 0.001
Holder voting power, description									The Series C Preferred Stock has a stated value of $24,000 and entitles the holder to 51% of the total voting power of the Company’s stockholders.
Series B Preferred Stock [Member]
Equity (Details) [Line Items]
Letter agreement, description								Upon execution of the note, $120,000 was remitted and the remaining $30,000 was remitted on September 22, 2020. The note did not bear interest. On November 10, 2020, the Company entered into an exchange agreement with Mr. Pollack. Pursuant to the exchange agreement, Mr. Pollack exchanged the promissory note issued August 31, 2020 for 15,000,000 shares of common stock of the Company.
Options [Member] | Danil Pollack [Member]
Equity (Details) [Line Items]
Employment agreement, description			Pursuant to the employment agreement, Mr. Pollack will serve as the Company’s chief executive officer and president for a period of one year, which term will renew automatically for successive one year terms, subject to the right of either party to terminate the agreement at any time upon written notice. Mr. Pollack was granted the right, for a period of six months, to purchase up to 100,000,000 shares of common stock of the Company for a purchase price of $0.001 per share. The Company recognized option expense of $1,416,975 during the year ended August 31, 2020. During the year ended August 31, 2020, Mr. Pollack exercised 84,000,000 stock options for $84,000. During the six months ended February 28, 2021, the remaining 16,000,000 stock options expired.

Equity (Details) - Schedule of

Equity (Details) - Schedule of warrants - Warrants [Member]	6 Months Ended
	Feb. 28, 2021USD ($)$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding Beginning balance | shares	3,450,000
Weighted-Average Price Per Share, Outstanding Beginning balance | $ / shares	$ 0.56
Weighted-Average Remaining Life, Outstanding Beginning years	2 years 292 days
Number of Warrants, Granted | shares
Weighted-Average Price Per Share, Granted | $ / shares
Number of Warrants, Canceled or expired | shares	(450,000)
Weighted-Average Price Per Share, Canceled or expired | $ / shares	$ 0.81
Number of Warrants, Exercised | shares
Weighted-Average Price Per Share, Exercised | $ / shares
Number of Warrants, Outstanding Ending balance | shares	3,000,000
Weighted-Average Price Per Share, Outstanding Ending balance | $ / shares	$ 0.52
Weighted-Average Remaining Life, Outstanding Ending years	2 years 193 days
Number of Warrants, Exercisable | shares	3,000,000
Weighted-Average Price Per Share, Exercisable | $ / shares	$ 0.52
Weighted-Average Remaining Life, Exercisable	2 years 193 days
Weighted-Average Price Per Share Intrinsic value | $

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of stock options - Options [Member]	6 Months Ended
	Feb. 28, 2021$ / sharesshares
Equity (Details) - Schedule of stock options [Line Items]
Number of Options, Outstanding Beginning balance | shares	16,000,000
Weighted-Average Price Per Share, Outstanding Beginning balance | $ / shares	$ 0.001
Weighted-Average Remaining Life, Outstanding Beginning years	328 days
Number of Options, Granted | shares
Weighted-Average Price Per Share, Granted | $ / shares
Number of Options, Canceled or expired | shares	(16,000,000)
Weighted-Average Price Per Share, Canceled or expired | $ / shares	$ 0.001
Number of Options, Exercised | shares
Weighted-Average Price Per Share, Exercised | $ / shares
Number of Options, Outstanding Ending balance | shares
Weighted-Average Price Per Share, Outstanding Ending balance | $ / shares
Number of Options, Exercisable | shares
Weighted-Average Price Per Share, Exercisable | $ / shares

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Jan. 06, 2021	Jan. 21, 2021	Nov. 30, 2020	Sep. 30, 2020	Aug. 31, 2020	Nov. 30, 2020	Jan. 05, 2021	Nov. 10, 2020
Related Party Transactions (Details) [Line Items]
Mr. Pollack an annual salary				$ 48,000
Outstanding shares (in Shares)								15,000,000
Non-interest bearing payable						$ 100,534
Amount deemed consideration	$ 100,000
Issued amount (in Shares)	5,000,000		500,000			500,000	500,000
Common stock aggregate shares (in Shares)		2,000,000	20,000,000
Common stock aggregate purchase price		$ 100,000	$ 200,000
Employment Agreement [Member]
Related Party Transactions (Details) [Line Items]
Promissory note, description					the Company issued a promissory note in the principal amount of $150,000, to Danil Pollack. Upon execution of the note, $120,000 was remitted and the remaining $30,000 was paid on September 22, 2020.
Chief Executive Officer [Member]
Related Party Transactions (Details) [Line Items]
Letter agreement, description					Pursuant to the exchange agreement, Mr. Pollack exchanged this note for 15,000,000 shares of common stock of the Company.

Commitments and Contingencies (

Commitments and Contingencies (Details)

Oct. 13, 2020USD ($)

Apr. 21, 2020USD ($)

Jun. 06, 2018USD ($)$ / shares

Nov. 30, 2021USD ($)shares

May 31, 2021USD ($)shares

Feb. 28, 2021USD ($)shares

Aug. 31, 2020USD ($)shares

Feb. 29, 2020USD ($)

Feb. 28, 2021USD ($)shares

Feb. 29, 2020USD ($)

Aug. 31, 2019USD ($)

Jan. 06, 2021shares

Jan. 05, 2021shares

Nov. 30, 2020shares

Commitments and Contingencies (Details) [Line Items]

Common stock issued (in Shares) | shares

5,000,000

500,000

500,000

Fees

$ 40,208

$ 93,411

$ 62,623

$ 148,786

Business days

5

5

Securities Purchase Agreement [Member]

Commitments and Contingencies (Details) [Line Items]

Common stock per share (in Dollars per share) | $ / shares

$ 0.10

Exercise price (in Dollars per share) | $ / shares

$ 0.10

Dividend

$ 50,000

Common stock issued (in Shares) | shares

500,000

Value of common stock

$ 76,000

Mr. Pollack an annual salary

$ 48,000

Subsequent Event [Member]

Commitments and Contingencies (Details) [Line Items]

Fees

$ 7,000

Business days

5

5

Minimum [Member]

Commitments and Contingencies (Details) [Line Items]

Monthly average sales

$ 200,000

$ 50,000

Minimum [Member] | Subsequent Event [Member]

Commitments and Contingencies (Details) [Line Items]

Monthly average sales

$ 100,000

$ 300,000

Maximum [Member]

Commitments and Contingencies (Details) [Line Items]

Common stock issued (in Shares) | shares

750,000

Monthly average sales

$ 300,000

$ 100,000

Maximum [Member] | Subsequent Event [Member]

Commitments and Contingencies (Details) [Line Items]

Monthly average sales

150,000

$ 500,000

Mr. Rozen [Member] | Subsequent Event [Member]

Commitments and Contingencies (Details) [Line Items]

Fees

$ 5,000

Mr. Rozen [Member] | Minimum [Member]

Commitments and Contingencies (Details) [Line Items]

Common stock issued (in Shares) | shares

1,500,000

500,000

1,500,000

Mr. Rozen [Member] | Minimum [Member] | Subsequent Event [Member]

Commitments and Contingencies (Details) [Line Items]

Common stock issued (in Shares) | shares

750,000

2,000,000

Mr. Rozen [Member] | Maximum [Member]

Commitments and Contingencies (Details) [Line Items]

Common stock issued (in Shares) | shares

2,000,000

2,000,000

Mr. Rozen [Member] | Maximum [Member] | Subsequent Event [Member]

Commitments and Contingencies (Details) [Line Items]

Common stock issued (in Shares) | shares

1,000,000

3,000,000

Consulting agreement [Member]

Commitments and Contingencies (Details) [Line Items]

Fees

$ 3,000

Major Customers (Details)

Major Customers (Details)	6 Months Ended	12 Months Ended
	Feb. 28, 2021	Aug. 31, 2020
Major Customers (Details) [Line Items]
Number of individual customer	0	0
Concentrations of credit risk	10.00%	10.00%
Accounts Receivable [Member]
Major Customers (Details) [Line Items]
Number of individual customer	0	0
Concentrations of credit risk	10.00%	10.00%